Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study. // Journal of Cystic Fibrosis. – URL: https://www.sciencedirect.com/science/article/pii/S1569199326016371?dgcid=rss_sd_all
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study. Journal of Cystic Fibrosis. https://www.sciencedirect.com/science/article/pii/S1569199326016371?dgcid=rss_sd_all
“Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study.” Journal of Cystic Fibrosis.
@article{article89783,
title = {Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study},
journal = {Journal of Cystic Fibrosis},
url = {https://www.sciencedirect.com/science/article/pii/S1569199326016371?dgcid=rss_sd_all}
}
ABSTRACT Aim To investigate the longitudinal association between early‐life movement behaviour patterns and later clinically diagnosed obesity. Method In the population‐based All Babies in Southeast Sweden (ABIS) cohort, 16 415 children...